Found 468 results in Expert Content

How can decisions made during the preclinical phase of drug development increase the chances of a product’s eventual success in a difficult marketplace?

Summary: Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes.

Get insights on using lipid systems during early development to achieve successful formulation and patient outcomes

Catalent’s experts presented technical posters on advanced drug design, discovery, development, delivery, packaging and scale-up. Click here to download [Part 1] of the 2015 AAPS posters Click here to...

Catalent with deep scientific expertise has the broadest capabilies and advancved technologies for controlled and modified release products.

This eBook published by Pharmaceutical Technology provides an overview of the regulatory landscape related to elemental impurities testing, discusses the challenges of implementing ICH Q3D guidelines ...

You will learn about a pharmaceutical company who was interested in scaling-up a multi-particulate, modified-release product to a commercial scale using fluid bed bottom-spray (Wurster) coating.

Summary: Given the accelerated timelines associated with expedited programs, lipid-based drug formulations, encapsulated in softgel capsules, provide an attractive option for addressing the challenges...

From the top industry partner for development, launch and supply of new treatments, Catalent offers integrated solutions for pulmonary and nasal delivery with significant capacity in North America. Our in-house capabilities span clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and multi-dose nasal sprays

Lipid based drug delivery systems (LBDDS) are the most studied and understood bioavailability enhancing solutions